Vanguard Group Inc Biocryst Pharmaceuticals Inc Call Options Transaction History
Vanguard Group Inc
- $4.96 Trillion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BCRX
# of Institutions
256Shares Held
182MCall Options Held
839KPut Options Held
816K-
Black Rock Inc. New York, NY18.4MShares$121 Million0.0% of portfolio
-
State Street Corp Boston, MA17.5MShares$114 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY13.1MShares$85.5 Million0.8% of portfolio
-
Baker Bros. Advisors LP New York, NY10.1MShares$66.3 Million0.65% of portfolio
-
Kynam Capital Management, LP Princeton, NJ6.53MShares$42.8 Million3.48% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.22B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...